Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0MT1N
|
||||
| Former ID |
DNC014091
|
||||
| Drug Name |
N-Ethyl-2-methylnorapomorphine hydrochloride
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H22ClNO2
|
||||
| Canonical SMILES |
CCN1CCC2=C3C1CC4=C(C3=CC(=C2)C)C(=C(C=C4)O)O.Cl
|
||||
| InChI |
1S/C19H21NO2.ClH/c1-3-20-7-6-13-8-11(2)9-14-17(13)15(20)10-12-4-5-16(21)19(22)18(12)14;/h4-5,8-9,15,21-22H,3,6-7,10H2,1-2H3;1H/t15-;/m1./s1
|
||||
| InChIKey |
VFIJPYCEACRORO-XFULWGLBSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | Bioorg Med Chem. 2009 Jul 1;17(13):4756-62. Epub 2009 May 3.N-Substituted-2-alkyl- and 2-arylnorapomorphines: novel, highly active D2 agonists. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.